EDMONTON, AB — February 11, 2026 — Leads & Copy — Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB) is expanding its Aurora® medical portfolio in Australia and New Zealand, offering patients and prescribers enhanced choice, reliable quality, and easier access to science-backed products.
The expansion highlights the company’s commitment to meeting the unique needs of patients and healthcare professionals in the region and reflects Aurora’s strategic focus on long-term global growth.
According to the news release, the expansion in New Zealand this month includes two new THC flower products – Big Wave™, Night Ride ™, as well as the balanced strain, Half Moon™ coming soon in Q1 FY27.
The brand will also debut four new resin cartridges in Australia this month, including Chemango™ Kush, Cosmic Cream™, Lunar Express™, and Soul Train Haze™.
Stanley Sack, Interim Managing Director of MedReleaf Australia, said that with Australia being one of Aurora’s largest international medical cannabis markets, both Australia and New Zealand remain a top priority for Aurora, and they are deeply committed to continued investment across the region.
Sack added that as patient needs evolve, so does Aurora’s responsibility to deliver high‑quality, diversified product formats that support prescribers in delivering better care, and their focus on quality and reliable supply reflects their dedication to ensuring patients have meaningful access to the products they depend on.
Each new product is derived from Aurora’s proprietary genetics and manufactured at the company’s leading EU-GMP and TGA-GMP certified facilities in Canada, ensuring the highest standards of quality and safety.
New Zealand Launches:
- Big Wave™ – Flower, Hybrid, THC 26%, CBD <1%
- Night Ride™ – Flower, Indica, THC 29%, CBD <1%
- Half Moon™ – Flower, Hybrid, THC 9%, CBD 13%
Australia Launches:
- Chemango™ Kush – Resin Cartridge, Indica, THC 780mg/g, CBD <10mg/g
- Cosmic Cream™ – Resin Cartridge, Indica, THC 780 mg/g, CBD <10mg/g
- Lunar Express™ – Resin Cartridge, Indica, THC 780mg/g, CBD <10mg/g
- Soul Train Haze™ – Resin Cartridge, Sativa, THC 780mg/g, CBD <10mg/g
Aurora remains a trusted choice for prescribers and patients around the globe. With a broad portfolio of high-quality medical cannabis, proven regulatory expertise, and strong leadership across a dozen markets, Aurora continues to raise the bar for supporting patient care.
Aurora serves both medical and consumer markets across Canada, Europe, Australia, and New Zealand, with a strategic focus on high-margin opportunities and a medical-first approach. Aurora’s portfolio of trusted, leading brands includes Aurora®, MedReleaf®, Pedanios®, IndiMed™, San Raf®, Tasty’s® and Whistler Medical Marijuana Co.®. The company also holds a controlling interest in Bevo Farms Ltd., North America’s leading supplier of propagated agricultural plants.
Aurora’s common shares trade on the NASDAQ and TSX under the symbol “ACB”.
Learn more at www.auroramj.com and follow on X and LinkedIn.
Source: Aurora Cannabis Inc.
